156740-78-2

Basic information

• Product Name: 2,6-dimethyl-4-nitrophenyl trifluoromethanesulphonate
• Synonyms: 2,6-dimethyl-4-nitrophenyl trifluoromethanesulphonate
• CAS NO: 156740-78-2
• Molecular Weight: 299.227
• Mol File: 156740-78-2.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: 2,6-dimethyl-4-nitrophenyl trifluoromethanesulphonate(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-dimethyl-4-nitrophenyl trifluoromethanesulphonate(156740-78-2)
• EPA Substance Registry System: 2,6-dimethyl-4-nitrophenyl trifluoromethanesulphonate(156740-78-2)

Safety Data

• Hazardous Substances Data: 156740-78-2(Hazardous Substances Data)

Upstream product

• 2423-71-4 2,6-dimethyl-4-nitro phenol 
• 358-23-6 trifluoromethylsulfonic anhydride 
• 1025373-45-8 trifluoromethanesulfonic acid anhydride 
• 37595-74-7 N,N-phenylbistrifluoromethane-sulfonimide 

Downstream Products

• 53906-84-6 2-bromo-1,3-dimethyl-5-nitrobenzene 
• 38560-96-2 2-chloro-1,3-dimethyl-5-nitro-benzene 
• 1393125-92-2 3,5-dimethyl-4-(4-(trifluoromethyl)-1H-imidazol-1-yl)phenol 
• 1393125-91-1 1-(2,6-dimethyl-4-nitrophenyl)-4-(trifluoromethyl)-1H-imidazole 
• 1425187-94-5 2,6-dimethyl-4-nitrophenyl(phenyl)sulfoxide 
• 1425187-95-6 2,6-dimethyl-4-nitrophenyl(4'-nitrophenyl)sulfoxide 
• 114660-00-3 2,6-dimethyl-4-nitrophenyl (phenyl) sulfide 
• 1425187-97-8 2,6-dimethyl-4-nitrophenyl (4'-nitrophenyl) sulfide 
• 1736-85-2 2-fluoro-1,3-dimethyl-5-nitrobenzene 
• 1425188-03-9 C₈H₈⁽¹⁸⁾FNO₂ 

Relevant articles and documents

New 4,4'-Bis(9-carbazolyl)-biphenyl derivatives with locked carbazole-biphenyl junctions: High-triplet state energy materials

We synthesized a series of 4,4'-bis(9-carbazolyl)-biphenyl (CBP) derivatives, using methyl groups as spatially demanding groups, locking the angle between the carbazole subunit and the biphenyl backbone as potential matrix material for blue organic light-

Glucagon Receptor Modulators

The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof wherein R1, R2, R3, A1, A2, A3, A4, L, B1, B2, B3 and B4 are as defined herein. The compounds of Formula I have been found to act as glucagon antagonists or inverse agonists. Consequently, the compounds of Formula I and the pharmaceutical compositions thereof are useful for the treatment of diseases, disorders, or conditions mediated by glucagon.

Therapeutic modulation of PPARgamma activity

Modulators of PPARγ activity are used in methods of treating and/or preventing conditions such as osteoporosis, Alzheimer's disease, psoriasis and acne, and cancer.